Switching Patients to Sialanar®
Guidance on switching patients from hyoscine or glycopyrronium bromide oral solutions to Sialanar®
Switching Patients to Sialanar®
Sialanar® 400 micrograms/ml oral solution for the symptomatic treatment of severe sialorrhoea (chronic pathological drooling) due to chronic neurological disorders of childhood-onset in patients aged 3 years and older.
Dose table for patients with normal renal function (mcg/kg doses refers to glycopyrronium bromide)1
Click on the patient's weight below to find the recommended dose
13-17 kg
18-22 kg
23-27 kg
28-32 kg
33-37 kg
38-42 kg
43-47 kg
≥48 kg
13-17 kg
-
Dose Level 1
~16 mcg/kg
0.6ml
-
Dose Level 2
~32 mcg/kg
1.2ml
-
Dose Level 3
~48 mcg/kg
1.8ml
-
Dose Level 4
~64 mcg/kg
2.4ml
-
Dose Level 5
~80 mcg/kg
3ml*
* Maximum individual dose in this weight range.
Dose table for patients with mild to moderate renal impairment (eGFR <90 to ≥30 ml/min/1.73m2) (mcg/kg doses refers to glycopyrronium bromide)1
Click on the patient's weight below to find the recommended dose
13-17 kg
18-22 kg
23-27 kg
28-32 kg
33-37 kg
38-42 kg
43-47 kg
≥48 kg
13-17 kg
-
Dose Level 1
~11 mcg/kg
0.4ml
-
Dose Level 2
~22 mcg/kg
0.8ml
-
Dose Level 3
~34 mcg/kg
1.2ml
-
Dose Level 4
~45 mcg/kg
1.7ml
-
Dose Level 5
~56 mcg/kg
2.1ml*
* Maximum individual dose in this weight range.
Please refer to the SmPC for full dosing information
Request a printed dosing wheel
Submit this form to request a printed dosing wheel to support you or your team:
Clinical Evidence
The first and only double-blind, randomised, placebo-controlled study of oral anticholinergics in sialorrhoea that has investigated efficacy, safety and impact on quality of life2,3 continued as an open-label study extension (OLSE)3